BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company, is continuing its progression of Bria-IMT for the treatment of advanced breast cancer. An article discussing the company reads, “The Bria-IMT phase I/IIa monotherapy study involved 23 patients who were very heavily pre-treated (a median of four previous systemic therapy regiments per patient). The treatment with Bria-IMT was well-tolerated, with minor local irritation at the injection site being reported as the most common adverse effect. … More importantly, Bria-IMT contributed to tumor shrinkage in three of the patients. The top respondent previously received seven rounds of chemotherapy and had tumor metastases at various sites. The patient’s three-month follow-up showed shrinkage in all 20 metastatic formations in the lungs. After six months, the response was still maintained. Two other patients also showed tumor reduction. All of the patients with tumor reduction matched Bria-IMT at one or more HLA types, validating BriaCell’s approach to selecting patients most likely to respond (BriaDx). Biological activity was observed in several other of the patients, and there was a noted decrease in circulating cancer-associated cells.”
To view the full article, visit http://nnw.fm/xWc9X
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]